Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.485 -0.045 (-2.94%)

Streaming Delayed Price Updated: 3:50 PM EST, Jan 6, 2026 Add to My Watchlist

Price and Volume

Volume	175,936
Open	1.510
Bid (Size)	1.470 (600)
Ask (Size)	1.500 (40,000)
Prev. Close	1.530
Today's Range	1.440 - 1.527
52wk Range	0.6302 - 2.600
Shares Outstanding	194,612,289
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

December 29, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

December 19, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Performance

YTD	-7.2%	-7.2%
1 Month	-11.1%	-11.1%
3 Month	-24.6%	-24.6%
6 Month	-2.9%	-2.9%
1 Year	+99.6%	+99.6%

More News

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

December 17, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Stock Rises On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’ ↗

September 25, 2025

Via Stocktwits

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

December 17, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

December 15, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

December 15, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

December 12, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

December 02, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

November 25, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

November 13, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Elon Musk Says Tesla, xAI Are 'Trending Towards Convergence' In Some Ways ↗

November 10, 2025

Via Benzinga

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

November 04, 2025

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

October 29, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

September 30, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

September 25, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

September 24, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

September 15, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

September 09, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Chairman

September 05, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

August 14, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

August 11, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Lucid Is Now Shipping Adapters That Let Customers Access Elon Musk-Led Tesla's Supercharger Network ↗

August 01, 2025

Via Benzinga

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

July 21, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 13, 2025

Via Benzinga

Frequently Asked Questions

Is Tiziana Life Sciences Ltd - Common Shares publicly traded?

Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.

What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?

Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?

The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market

What is the current price of Tiziana Life Sciences Ltd - Common Shares?

The current price of Tiziana Life Sciences Ltd - Common Shares is 1.485

When was Tiziana Life Sciences Ltd - Common Shares last traded?

The last trade of Tiziana Life Sciences Ltd - Common Shares was at 01/06/26 03:50 PM ET

What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?

The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 289.00M

How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?

Tiziana Life Sciences Ltd - Common Shares has 289M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.